Could Germany’s free-pricing period be cut in half?
Drug-makers currently enjoy a year of free pricing in Germany, before the impact of an added-benefit assessment kicks in. According to Josef
Our latest thinking, insights and company news
Never miss an update, subscribe today.
RJW&partners will only use your personal information to administer your account and provide the products and services you request. You can unsubscribe at any time, to do so please review our Privacy Policy. By clicking subscribe, you consent to allow RJW&partners to store and process your personal information.
